Literature DB >> 1406283

Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae.

R Muñoz1, C G Dowson, M Daniels, T J Coffey, C Martin, R Hakenbeck, B G Spratt.   

Abstract

Resistance to third-generation cephalosporins in a clinical isolate of Streptococcus pneumoniae was shown to be due to the production of altered forms of penicillin-binding proteins (PBPs) 2X and 1A. The cloned PBP2X gene from the resistant strain was able to transform a susceptible strain to an intermediate level of resistance. The resulting transformant could be transformed to the full level of resistance of the clinical isolate using the cloned PBP1A gene from the latter strain. Chromosomal DNA from the resistant strain (and from other resistant strains) could readily transform a susceptible strain to the full level of resistance to third-generation cephalosporins (greater than 250-fold for cefotaxime; greater than 100-fold for ceftriaxone) in a single step (transformation frequency of about 10(-5)). The resistant transformants obtained with chromosomal DNA were shown by gene fingerprinting to have gained both the PBP1A and PBP2X genes from the DNA donor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1406283     DOI: 10.1111/j.1365-2958.1992.tb01422.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  72 in total

1.  Mutational analysis of the Streptococcus pneumoniae bimodular class A penicillin-binding proteins.

Authors:  J Paik; I Kern; R Lurz; R Hakenbeck
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

2.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Relative sensitivities of Streptococcus pneumoniae strains to penicillin and ceftriaxone.

Authors:  D S Hodes; T E Sudol
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  Emergence of a pneumococcal clone with cephalosporin resistance and penicillin susceptibility.

Authors:  A M Smith; R F Botha; H J Koornhof; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin.

Authors:  C Doit; C Loukil; F Fitoussi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Functional characterization of penicillin-binding protein 1b from Streptococcus pneumoniae.

Authors:  Anne Marie Di Guilmi; Andréa Dessen; Otto Dideberg; Thierry Vernet
Journal:  J Bacteriol       Date:  2003-03       Impact factor: 3.490

Review 7.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.

Authors:  S J Schrag; B Beall; S F Dowell
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

8.  BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins.

Authors:  G Zhao; T I Meier; S D Kahl; K R Gee; L C Blaszczak
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

9.  Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates.

Authors:  Y Asahi; Y Takeuchi; K Ubukata
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

10.  Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.

Authors:  Klaudia Kosowska-Shick; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.